HK Stock Market Move | AIM VACCINE (06660) rose more than 13% during trading hours as the mRNA respiratory syncytial virus vaccine was approved by the US FDA for clinical trials.

AIM VACCINE (06660) rose more than 13% during trading hours, and at the time of writing, it was up 8.91% at HK$6.11 with a turnover of HK$101 million. In terms of news, AIM VACCINE announced that the group's mRNA respiratory syncytial virus vaccine has recently received clinical trial approval from the US Food and Drug Administration (FDA). This is also the first time the group's product has been approved for clinical use by the US FDA, marking a significant step forward in the group's internationalization strategy. In preclinical animal trials, third-party testing results showed that the specific IgG antibody titers, virus neutralizing antibody titers, and specific T-cell immunity of the group's mRNA respiratory syncytial virus vaccine were significantly higher than those of the internationally marketed mRNA respiratory syncytial virus control vaccine. It is worth mentioning that AIM VACCINE is actively responding to the national "AI+" industry development strategy, and has fully deployed the DeepSeek large model to promote the application of the DeepSeek R1 version in the group's entire business scenarios through localization strategies, achieving "cost reduction, quality improvement, and efficiency enhancement" for the entire life cycle of vaccines. The company stated that by fully integrating the DeepSeek large model, AI technology will be deeply integrated into the entire industry chain of research and development, production, sales, management, etc., providing AI solutions for global immune prevention and control.